All In Biotech

Drug Trial Radar · NCT05894707

Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

A Randomized, Double-blinded, Dose-escalation Phase Ia Study to Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jun 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

32

Planned (sponsor's estimate)

Start

Jun 2023

Primary completion

Nov 2023

Study completion Mar 2024

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Jun 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of clinical trial is to evaluate the safety and tolerability of SCT650C in healthy participants.

Conditions

  • Autoimmune Disease

Interventions

  • SCT650CDrug

    Recombinant anti-IL-17A antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Baseline (Day 1, IP administration) up to 24 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research - Joonadalup

    Joondalup, Western Australia, Australia

  • Linear Clinical Research - B Block

    Nedlands, Western Australia, Australia

  • Linear Clinical Research - Harry Perkins

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.